Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
The BioCentury Show
BioCentury
Nacktes Geld
Paul Brandenburg
EntreArchitect Podcast with Mark R. LePage
EntreArchitect // Gābl Media
Optimizing Your Google Business Profile for Maximum Visibility
GMB Crush
AgWatchers
Andrew Whitelaw & Matt Dalgleish
Brushwood Media Network
Brushwood Media Network
Abraham Hicks’s Podcast
Abraham Hicks
WW – William Waack
CNN Brasil
Abraham Hicks
Abraham Hicks
Ekantik Vartalap
Bhajan Marg
Abraham Hicks’s Podcast
Abraham Hicks
The Invisible Hand
Emma Reid
Inside the Mind of Champions
Jeremy Snape
Happier At Work: Leadership, Culture, Performance
Aoife O'Brien
MENTOR360
Luis Ramos
Living the Dream with Curveball
curveball
El Club de Inversión podcast
El Club de Inversión
5THWAVE - The Business of Coffee and Hospitality
World Coffee Portal
Pharma and BioTech Daily
Pharma and BioTech News
UnMotivated
Trevor aka "The Dog Father"
Digimasters Shorts
Adam Nagus, Carly Wilson
SEO for Established Entrepreneurs: The Basic B
Brittany Herzberg | SEO Coach & Lead Gen Strategist
Lead with Confidence
JP Warren
Managing Care Quality
Lesley Shaw
Uncensored Renegades
Jon Evans and Kory Marchisotto
NewIn Podcast
Cathi Harrison
Business As Usual | City AM
City AM
Money Penny
Hospodářské noviny
MoneywebNOW
Moneyweb Radio
EconomX Podcast
economx.hu
The Quarter Hour: the best daily radio industry podcast
podtential originals
Noticias Marketing
Borja Girón
Survive: Essentials for C-Store Assistant Managers
C-Store Center
Thrive: Leadership Skills for C-Store Managers
C-Store Center
Drive: Multi-Unit Excellence for C-Store District Managers
C-Store Center
Arrive: Strategy for Independent C-Store Owners
C-Store Center
CFO Podcast
Peter De Roeck
Business
BioCentury
Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could s...
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank...
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in S...
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The...
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing th...
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on The BioCen...
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, accordi...
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-fou...
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting s...
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI...
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower re...
Caution: This episode of The BioCentury Show contains strong language.In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slo...
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypoth...
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move id...
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to con...
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary s...
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by techno...
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.If you c...
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic ca...
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.